Immunovant (IMVT)
(Delayed Data from NSDQ)
$28.42 USD
-0.38 (-1.32%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $28.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Company Summary
Headquartered in New York, Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. The company is developing its lead candidate, IMVT-1402, a novel, a fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor (FcRn). It is evaluating IMVT-1402 in an ongoing early-stage study for the treatment of several autoimmune diseases mediated by pathogenic IgG antibodies, reporting positive top-line data last year. IMVT-1402 is being developed as a pre-filled subcutaneous (SC) injection.
Immunovant expects to initiate several late-stage potentially registrational studies for ...
Company Summary
Headquartered in New York, Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. The company is developing its lead candidate, IMVT-1402, a novel, a fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor (FcRn). It is evaluating IMVT-1402 in an ongoing early-stage study for the treatment of several autoimmune diseases mediated by pathogenic IgG antibodies, reporting positive top-line data last year. IMVT-1402 is being developed as a pre-filled subcutaneous (SC) injection.
Immunovant expects to initiate several late-stage potentially registrational studies for IMVT-1402 across several autoimmune indications, including Graves’ disease (GD), Myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and thyroid eye disease (TED).
The company is developing its other pipeline candidate, batoclimab (formerly IMVT-1401), for several IgG-mediated autoimmune indications, including, MG, TED, CIDP and GD, in separate clinical studies. Immunovant expects to leverage the data from its batoclimab program, along with publicly disclosed in-class competitor data, to establish proof-of-concept as well as provide insights into potentially more informative study designs for impending registrational studies for IMVT-1402.
Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. (RSL). Immunovant came into existence in 2019 after Health Sciences Acquisitions Corporation acquired 100% of the issued and outstanding shares in Immunovant Sciences Ltd. Upon closing, the combined company was named Immunovant, Inc., which began trading on Nasdaq under the symbol IMVT from Dec 19, 2019.
In December 2017, Roivant Sciences GmbH (RSG), a wholly-owned subsidiary of RSL, entered the HanAll agreement. Per the agreement, RSG received the non-exclusive right to manufacture and exclusively develop, import and use batoclimab and commercialize it in the United States, and EU during the term of the agreement. However, in December 2018, the company obtained and assumed all rights and obligations under the HanAll agreement from RSG, including all rights to batoclimab from RSG in all licensed territories.
General Information
Immunovant, Inc
320 WEST 37TH STREET
NEW YORK, NY 10018
Phone: 917-580-3099
Fax: NA
Web: http://www.immunovant.com
Email: info@immunovant.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | March |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/14/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.62 |
Current Year EPS Consensus Estimate | -2.43 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/14/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 28.80 |
52 Week High | 45.58 |
52 Week Low | 24.67 |
Beta | 0.67 |
20 Day Moving Average | 1,114,690.62 |
Target Price Consensus | 49.36 |
4 Week | -9.21 |
12 Week | 8.60 |
YTD | -31.64 |
4 Week | -10.90 |
12 Week | 4.36 |
YTD | -43.12 |
Shares Outstanding (millions) | 146.37 |
Market Capitalization (millions) | 4,215.38 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -27.66% |
vs. Previous Quarter | -15.38% |
vs. Previous Year | NA% |
vs. Previous Quarter | NA% |
Price/Book | 7.74 |
Price/Cash Flow | NA |
Price / Sales | NA |
6/30/24 | -52.07 |
3/31/24 | -53.40 |
12/31/23 | -57.97 |
6/30/24 | -48.25 |
3/31/24 | -48.85 |
12/31/23 | -52.47 |
6/30/24 | 13.09 |
3/31/24 | 13.70 |
12/31/23 | 22.14 |
6/30/24 | 13.08 |
3/31/24 | 13.70 |
12/31/23 | 22.14 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | 3.72 |
3/31/24 | 4.25 |
12/31/23 | 4.70 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |